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Study objective: To examine the prevalence of circadian misalignment in clinically diagnosed 
DSPD, and compare mood and daytime functioning in those with and without a circadian basis for 
the disorder. 
Methods: 182 DSPD patients aged 16 to 64 years, engaged in regular employment or school, 
underwent sleep-wake monitoring in the home, followed by a sleep laboratory visit for assessment 
of salivary dim light melatonin onset (DLMO). Based on the DLMO assessments, patients were 
classified into two groups: circadian DSPD, defined as DLMO occurring at or after desired 
bedtime, or non-circadian DSPD, defined as DLMO occurring before desired bedtime. 
Results: 103 patients (57%) were classified as circadian DSPD and 79 (43%) as non-circadian 
DSPD. DLMO occurred 1.66 h later in circadian DSPD compared to non-circadian DSPD 
(p<0.001). Moderate-severe depressive symptoms (Beck Depression Inventory-II) were more 
prevalent in circadian DSPD (14.0%) than in non-circadian DSPD (3.8%; p<0.05). Relative to 
non-circadian DSPD patients, circadian DSPD patients had 4.31 times increased odds of at least 
mild depressive symptoms (95% CI 1.75 to 10.64, p<0.01). No group differences were found for 
daytime sleepiness or function, but DSPD symptoms were rated by clinicians to be more severe in 
those with circadian DSPD.  
Conclusions: Almost half of patients clinically diagnosed with DSPD did not show misalignment 
between the circadian pacemaker and the desired bedtime, suggesting that the reported difficulties 
initiating sleep at the desired bedtime are unlikely to be explained by the (mis)timing of the 
circadian rhythm of sleep propensity. Circadian misalignment in DSPD is associated with 
increased depressive symptoms and DSPD symptom severity.  




Delayed Sleep Phase Disorder (DSPD) is a highly prevalent, often undiagnosed primary 
circadian sleep disorder, caused by a delay in the endogenous circadian clock. Here we 
demonstrated that almost 50% of patients clinically diagnosed with DSPD did not show evidence 
of having a delay in circadian clock relative to desired bedtime, suggesting a non-circadian 
etiology for their sleep complaints. Additionally, we found that those with circadian 
misalignment showed significantly elevated depressive symptoms, providing further evidence for 
a circadian basis for mood disturbances. These findings support the measurement of the 
melatonin rhythm to distinguish patients with and without circadian misalignment, as a part of 
the routine diagnostic process. Furthermore, measurement of the melatonin rhythm may improve 
treatment outcomes by more accurately phenotyping patients to identify those who are likely to 
benefit from chronobiological treatments, and to optimise the timing of chronobiological 







Delayed Sleep Phase Disorder (DSPD) is a circadian rhythm sleep disorder (CRSD) characterized 
by a delay in the major sleep episode relative to the desired or required sleep-wake cycle, resulting 
in difficulty both initiating sleep and subsequently awakening at the desired or required clock 
times1. DSPD is more prevalent in teenagers and young adults (7-16%)1 than in middle-aged adults 
(3.1%)2.  
DSPD is associated with significant functional impairments. Adult DSPD patients report 
significant impairments to job performance, financial difficulties and marital problems3, and also 
greater medication use, particularly hypnotics4. Adolescents with DSPD show poorer school 
performance5,6, dysfunctional school behaviors, underachievement7, and are more likely to engage 
in negative health behaviors such as smoking8, and excessive alcohol6 and caffeine use9. 
Depressive symptoms are commonly reported in DSPD patients10. Abe and colleagues showed 
that 64% of patients with DSPD had a comorbid diagnosis of depression11. In a survey of 917 
consecutive sleep clinic patients, 41% of DSPD patients showed evidence of depressive 
symptoms12. Preliminary findings suggest that treatment of DSPD with exogenous melatonin 
significantly improved depressive symptoms13.  
The higher rate of depression in the DSPD population is perhaps not surprising, as circadian 
misalignment appears to play a role in the pathophysiology of mood disorders14, particularly 
depression15,16, although the precise mechanisms underlying the associations are unclear. 
Disruption of the circadian system increases vulnerability to major depression17,18, and specific 
polymorphisms in the core circadian clock genes CLOCK, BMAL1, PERIOD3 and TIMELESS are 
associated with increased risk of mood disorders19. Furthermore, short sleep duration, which is 
common in DSPD patients, may interact with a vulnerability generated by a polymorphism in the 
serotonin transporter gene (5-HTTLPR in SLC6A4) to increase the risk of depression in DSPD20.  
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In clinical practice, DSPD as a circadian disorder is often not easily differentiated from sleep 
initiation insomnia, particularly in the absence of an objective and reliable diagnostic test for 
DSPD. Therefore, some patients classified as having DSPD based on current diagnostic criteria, 
which rely predominantly on self-reported symptoms21,22, may not show a delay in the timing of 
the circadian pacemaker23-26 and be incorrectly diagnosed. Separate from the circadian 
mechanisms that underlie DSPD, DSPD-like symptoms may be attributed to reduced homeostatic 
sleep pressure leading to increased evening alertness27, poor sleep hygiene28, and pre-sleep 
hyperarousal29,30. Different treatment approaches are likely needed to effectively manage DSPD 
symptoms depending on the specific etiology. 
We investigated the timing of the melatonin rhythm relative to desired sleep time in patients with 
clinically diagnosed DSPD1, to determine the proportion of DSPD attributable to circadian 
misalignment. Patients were classified into circadian and non-circadian DSPD types based on a 
laboratory-based circadian phase assessment using salivary Dim Light Melatonin Onset (DLMO). 





This multi-center study was approved by the Monash University Human Research Ethics 
Committee, The University of Sydney Human Research and Ethics Committee, Southern Adelaide 
Clinical Human Research Ethics Committee, and The University of Adelaide Human Research 
Ethics Committee. All participants provided written informed consent and were reimbursed for 
study-related expenses. The current study was part of a larger randomized controlled trial testing 




One hundred and eighty-two participants (89 M, 93 F) aged between 16 to 64 years, with a body 
mass index (BMI) between 18 and 35 kg/m2, were recruited at three study sites: Melbourne 
(Monash University), Sydney (Woolcock Institute of Medical Research) and Adelaide (Flinders 
University). Participants were recruited from the community via radio, newspaper, television and 
poster advertisements, and referrals from sleep physicians, general practitioners and psychologists. 
Participants met diagnostic criteria for DSPD1 based on clinical interview by a sleep physician. 
Additionally, we did not specifically exclude participants with sleep initiation insomnia as this type of 
insomnia is not easily differentiated from the symptoms of DSPD. See Figure 1 and supplemental 
material for detailed inclusion/exclusion criteria.  
 
 
Circadian and non-circadian DSPD phenotypes 
Participants were classified into phenotype groups based on the relationship between DLMO and 
desired bedtime (DBT). A circadian DSPD phenotype was defined as having a DLMO time at or 
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after DBT. To allow for potential measurement error in DLMO and/or DBT, those with DLMO 
occurring up to 30 minutes before DBT were also classified as circadian DSPD. The non-circadian 
DSPD phenotype was defined as having a DLMO time > 30 min before DBT. DBT was derived 
from the following question: “On the night before school or work, what time would you need to 
go to bed in order to feel fully rested in the morning?”31. 
Given that the diagnostic criteria for DSPD refer to required or desired bedtime (Criterion A)32, 
our definition of circadian DSPD phenotype was based on the timing of the onset of melatonin 
synthesis relative to desired or required bedtime, rather than actual bedtime, which may be driven 
by social demands or constraints. In healthy individuals, melatonin onset occurs on average ~2 
hours before sleep onset33. In our patient population, we first determined whether or not desired 
bedtime differed from habitual bedtime. If it did, we then examined whether or not DLMO was 
appropriately timed relative to desired sleep time. We assumed that if desired bedtime occurred at 
least 30 minutes after DLMO, the timing of DLMO (and, by extrapolation, the circadian rhythm 
of sleep propensity) was unlikely to be the primary cause of the reported difficulty initiating sleep 
at the desired bedtime (i.e. the hallmark symptom of DSPD). 
 
Screening 
Participants completed: online questionnaires assessing DSPD symptoms31, sleep-wake habits, 
sleep impairments, daytime functioning and diurnal preference34 (see supplemental material for 
details); further screening by telephone; formal screening visit after providing written informed 
consent; and a clinical consultation with a physician specializing in sleep medicine. In addition to 
confirming diagnosis of DSPD1, the physician rated symptom severity and duration using the 





Participants were asked to maintain their usual sleep-wake patterns and were monitored for at least 
7 days immediately prior to a laboratory visit using a sleep diary, verified by wrist actigraphy 
(Actiwatch Spectrum, Philips Respironics, Bend, OR, USA). In cases of actigraphy malfunction 
or non-compliance (n=13, 7.03%), participants were required to repeat the sleep-wake monitoring. 
Participants also completed a daytime activity diary to record daytime work, school or study 
commitments.  
The Morningness-Eveningness Questionnaire was used to determine diurnal preference based on 
established cut-off scores for these categories34. To increase probability of DSPD, at preliminary 
screening, those with a composite score greater than 49, indicating that they were either 
intermediate or morning types, were excluded from the study. 
Mean self-reported habitual bedtime, habitual sleep time, and total sleep time were calculated from 
sleep diaries over 7 consecutive days. 
 
Daytime sleepiness and functioning 
Prior to the laboratory visit, participants completed an online questionnaire including the 
following: Epworth Sleepiness Scale (ESS)36, Sheehan Disability Scale (SDS)37, and Beck 
Depression Inventory, Second Edition (BDI-II)38 (see supplemental material). The ESS was 
collapsed into two categorical variables based on the recommended reference range of 0-10 
(normal) and greater than 10 (excessive daytime sleepiness)39.  
 
Circadian phase assessment 
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After the sleep-wake assessment, participants attended the laboratory for measurement of circadian 
phase. Participants arrived 6 hours before their self-reported habitual sleep onset time, and 
remained in a light-proof, sound attenuated and temperature-controlled suite until at least 2 hours 
after their habitual sleep onset time. Ambient light levels were maintained at <10 lux (measured 
in the direction of gaze at standard height of seated position; vertical plane, 137 cm from floor40-
42) and saliva samples (~2 mL) were collected hourly from 5 hours before to 2 hours after habitual 
sleep onset time. Participants were instructed to remain seated for 20 minutes and were not 
permitted to consume food or beverages for 10 minutes before each sample. They were permitted 
to watch television (<10 lux), read and engage in quiet activities between samples, but were 
required to remain awake for the duration of the visit, monitored by direct observation. Samples 
were collected (Salivette, Sarstedt, Numbrecht, Germany) as previously described43, centrifuged 
and stored immediately at -20°C. After the final sample collection, participants were transported 
to their homes. 
 
Dim Light Melatonin Onset (DLMO): Saliva (200μl) was assayed in duplicate for melatonin by 
radioimmunoassay44 within 1 week of collection, using procedures developed by University of 
Adelaide and licensed to Buhlmann Laboratories (Allschwil, Switzerland). Limit of detection of 
the assay was 1pg/mL and the inter-assay CVs were 7.4% at 4.41pg/mL and 10.7% at 48.14pg/mL. 
DLMO for each participant was determined as the time that melatonin concentrations crossed and 
remained above a threshold of 2.3pg/mL, calculated from linear interpolation between the samples 




SPSS Statistics Version 20.0 (IBM, Armonk, New York) was used for all data analysis. Data are 
expressed as mean ± standard deviation (SD) unless otherwise stated. Significance level was 0.05. 
Mood, as assessed by BDI-II, was defined as the primary outcome. BDI-II scores were categorized 
as follows: minimal depression (0-13); mild (14-19); and moderate-severe (20-63)38. Variables 
were compared between circadian and non-circadian DSPD phenotypes using chi-squared 
(goodness of fit) test or independent samples t-test.  
A direct logistic regression was conducted to assess the association between DSPD phenotypes 
and depression symptom severity (minimal vs. mild-severe depression symptoms). Age, sex, total 







Participants were 29.8 ± 10.6 years (range 16 to 64 years) with BMI 24.7 ± 4.0 kg/m2. Despite 
being clinically diagnosed with DSPD, 79 participants (43%) did not show an abnormal phase 
relationship between DLMO time and DBT, and were thus classified as non-circadian DSPD 
phenotype. The remaining 103 participants (57%) were classified as circadian DSPD phenotype.  
No significant differences were found between DSPD phenotype groups in age, BMI, sex or nature 
of work or study commitments, although we observed a trend for circadian DSPD phenotype to be 
younger (see Table 1).  
Circadian and non-circadian DSPD phenotypes did not show differences in desired or habitual 
bedtimes on nights before work and non-work days, and wake times on work days (see Table 2). 
Wake time on non-work days, however, was significantly later in the circadian DSPD group 
compared to the non-circadian DSPD group (mean difference 0.80 hours; 95% confidence interval 
[CI] 0.30 to 1.30; p<0.01). Circadian and non-circadian DSPD phenotypes did not show 
differences in diurnal preference (Table 2).  
 
Circadian phase relationships with bedtime and sleep time 
DLMO clock time for the circadian DSPD phenotype participants was on average 1.66 h later than 
the non-circadian DSPD phenotype participants (p<0.001; 95% CI 1.30 to 2.02). On average, those 
with a circadian DSPD phenotype had a DLMO time that occurred 0.65 ± 0.90 hours after DBT 
(range: DLMO occurred 0.50 hours before to 3.22 hours after DBT), compared with those with a 
non-circadian DSPD phenotype in whom DLMO occurred 1.48 ± 0.78 hours before DBT (range: 
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DLMO occurred 3.43 hours to 0.52 hours before DBT; p<0.001; 95% CI 1.88 to 2.38) (Figure 
2A).  
DLMO occurred on average 1.90 ± 1.07 hours before habitual sleep time (range: 4.88 to 0.73 
hours) in the circadian DSPD phenotype group, and 3.20 ± 1.06 hours before habitual sleep time 




Overall, 24.2% of the sample showed mild-severe depression symptoms (BDI-II score ≥14), and 
9.6% showed moderate-severe depression symptoms (BDI-II score ≥ 20). Of those reporting mild-
severe depression symptoms, 81% had a circadian DSPD phenotype (Figure 2B). Mean BDI-II 
score was higher in the circadian DSPD phenotype (10.55 ± 10.20) than the non-circadian 
phenotype (7.24 ± 6.02) (p<0.01). A significantly greater proportion of participants in the circadian 
DSPD group reported mild-severe depression symptoms (35.0%) compared with the non-circadian 
DSPD participants (10.3%; p<0.001; Figure 3). Likewise, a significantly greater proportion of 
participants in the circadian DSPD group reported moderate-severe depression symptoms (14.0%) 
compared with the non-circadian DSPD participants (3.8%; p<0.05). 
In post-hoc analyses, we excluded 11 participants who reported current antidepressant medication 
use (6.0% of sample) and found that depressive symptoms remained significantly higher in those 
with a circadian DSPD phenotype (10.44 ± 10.36, n = 95) compared to those with the non-circadian 
phenotype (7.17 ± 5.01, n = 76, p<0.05).  
We assessed the association between DSPD phenotype and depression symptoms (minimal 
depressive symptoms vs. mild-severe depressive symptoms), controlling for age, sex, total sleep 
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time and habitual sleep time. Those with the circadian DSPD phenotype were found to have greater 
odds of reporting mild-severe depressive symptoms (adjusted odds ratio [AOR] 4.31, 95% CI 1.75 
to 10.64, p<0.01). Current anti-depressant medication use was not significant in the model and 
therefore was not included in the final analysis. 
To further examine the relationship between circadian misalignment and depression, we compared 
the phase difference between DLMO and DBT in those with mild-severe depressive symptoms to 
those with minimal depressive symptoms. In those with mild-severe depressive symptoms, DLMO 
occurred 0.49 ± 1.30 hours after DBT (range: DLMO 2.80 hours before to 3.13 hours after DBT), 
whereas DLMO occurred 0.51 ± 1.31 hours before DBT (DLMO; range: DLMO 3.43 before to 
3.22 hours after DBT) in those with minimal depressive symptoms (95% CI 1.45 to -0.56; 
p<0.001).  
 
Sleepiness and Daytime Function 
There were no significant group differences in the questionnaire-based assessments for sleepiness 
(χ2(1)=0.393, p=0.531), or daytime functioning (t(177)=0.704, p=0.482; Table 2).  
 
Clinical Severity Assessment 
On the clinician-rated CGI-S, completed before the assessment of circadian phase, more 
participants in the circadian DSPD phenotype group were classified as moderately-severely ill 
(n=63; 61.2%) compared with the non-circadian phenotype group (n=33, 42.9%; χ2(1)=5.934, 





This study examined the phase of the circadian melatonin rhythm relative to the desired sleep-
wake cycle in a sample of DSPD patients, and compared mood and daytime function in patients 
with and without a circadian phase misalignment. There are two key findings. First, we showed 
that almost half (43%) of patients with a clinical diagnosis of DSPD did not have misaligned timing 
of the melatonin rhythm, and were therefore misdiagnosed with a circadian rhythm sleep disorder. 
Second, those with misaligned timing of the melatonin rhythm relative to the desired sleep-wake 
cycle reported a higher prevalence and severity of depressive symptoms than those who did not 
have misaligned rhythms. Clinician assessments, made prior to circadian phase assessment, 
showed that a higher proportion of the patients who have misaligned timing of the melatonin 
rhythm have moderate-severe illness severity compared with those without circadian 
misalignment. These findings demonstrate that in patients with DSPD symptoms, those who have 
objectively-assessed circadian misalignment report greater depressive symptoms and illness 
severity.  
To our knowledge, this is the first study to examine circadian phase relative to desired bedtime in 
a clinically diagnosed DSPD sample, showing that a high proportion of patients are misdiagnosed 
with a circadian rhythm sleep disorder. Interestingly, despite its recognized circadian etiology, 
current diagnostic criteria do not include assessment of circadian phase, using markers such as 
DLMO32,46. In the current study, 43% of patients who were clinically diagnosed with DSPD were 
found to have no evidence of circadian misalignment (i.e., DLMO occurred at 30 min or more 
before desired bedtime). This finding supports the contention22,47,48 that circadian phase 
assessment should become part of the standard diagnostic evaluation for DSPD to better differentiate 
phenotypes and optimize the treatment regime based on the underlying etiology. Cost effectiveness and 
reimbursement options for DLMO as a diagnostic tool remain to be evaluated. 
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One reason for determining the objective presence of circadian misalignment is that individual 
DLMO information may have implications for therapy. While those with circadian misalignment 
may benefit from treatments that specifically target the circadian system, such as light-dark 
exposure and/or melatonin (agonist) therapy49-52, as well as other treatments such as cognitive 
behavioral therapy for insomnia53, those without circadian misalignment are not likely to benefit 
from the targeted circadian interventions. Therefore, DLMO assessment may provide information 
that enables a more targeted therapeutic approach to patients with symptoms of DSPD. 
Based on subjective sleep-wake assessments, which form the basis of current diagnostic criteria 
for the disorder, those with and without circadian misalignment were relatively indistinguishable. 
This is unsurprising, given that there can be considerable inter-individual variability in phase 
relationships between the melatonin rhythm and the sleep-wake cycle, despite similar sleep-wake 
schedules33,43,54,55. There is also substantial intra-individual variability observed in the current 
study, as evidenced by the difference in phase relationships between the melatonin rhythm and 
habitual bedtime on work and non-work nights. Habitual bedtime and wake time and DBT were 
not significantly different between groups on work nights, but habitual wake time on non-work 
days was significantly later in the circadian DSPD phenotype group compared to the non-circadian 
DSPD group, consistent with the significantly later timing of the melatonin rhythm in this group.  
Previous studies have reported associations between circadian rhythm misalignment and depressed 
mood56,57. In seasonal depression, depressive symptom severity is strongly related to the degree of 
circadian rhythm misalignment58. High rates of depression have also been reported in DSPD 
patients10,11. A previous study (n=20) showed abnormal timing of the urinary melatonin metabolite 
rhythm in DSPD patients with depressive symptoms compared to those without depressive 
symptoms13. Our study shows that circadian misalignment in patients clinically diagnosed with 
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DSPD is strongly associated with depressive symptoms, even after controlling for total sleep time 
and other potential confounding variables; those in the circadian DSPD group had 4.31 times 
increased odds of reporting at least mild depressive symptoms. The relationship between circadian 
misalignment and depressive symptoms was further supported by the finding that in those with at 
least mild depressive symptoms, DLMO occurred 0.5 hours after DBT, while DLMO occurred 0.5 
h before DBT in those with minimal depressive symptoms.  
Whilst the exact mechanisms linking circadian misalignment and mood disturbances are not yet 
fully understood, there is evidence that the genes associated with circadian misalignment may 
contribute to susceptibility to mood disorders19. Polymorphisms of circadian clock genes such as 
CLOCK, PER2 and PER3 are reported to be associated with extreme evening preference59-62; 
although not all studies agree63-66. Some of these genes are also associated with an increased 
susceptibility to mood disorders67,68, providing a possible genetic basis for the observed 
associations. In our study, DLMO occurred almost 2 hours later in the circadian DSPD phenotype 
group in conjunction with higher depressive symptoms. The circadian DSPD phenotype on 
average wakes up closer to the time of the nadir of the body temperature rhythm, which is also the 
nadir of positive affect69. Frequent experience of low positive affect in the mornings may 
contribute to the increased depressive symptoms of the circadian DSPD group. 
Chronic sleep deficiency and delayed sleep timing70,71 are both associated with increased risk of 
depression, and are commonly experienced by DSPD patients72. In our analysis, however, by 
including both the duration and timing of sleep as potential confounders, we showed that 
misaligned timing of the melatonin rhythm relative to the desired sleep-wake cycle is 
independently associated with depressive symptoms. Finally a missense variant (P10L) of the 
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melanopsin gene is associated with predisposition to seasonal depression73, indicating that 
alteration in circadian light sensitivity may contribute to mood disturbances. 
In those individuals diagnosed with DSPD but found to have no circadian misalignment, factors 
that may contribute to the DSPD-like sleep complaints include decreased rate of accumulation of 
homeostatic sleep pressure27 and psychophysiological factors that increase pre-sleep arousal, such 
as anxiety29. Hiller and colleagues30 recently reported that sleep initiation in adolescents is 
impeded by cognitive processes such as catastrophizing as well as anxiety, although their study 
did not measure circadian phase. While our study did not include participants with a current 
diagnosis of an anxiety disorder, because we did not specifically screen for such disorders, it is 
possible that those with undiagnosed anxiety disorders were included. These factors could help 
explain why sleep initiation is difficult in the non-circadian DSPD phenotype, despite having a 
normal circadian phase. 
No group differences were observed for self-reported measures of daytime sleepiness or functional 
impairments. Notably, however, DSPD patients in both groups reported a relatively high level of 
absenteeism and lost productivity, consistent with our previous report31, and other studies reporting 
poorer work/academic outcomes associated with DSPD1,3. We found that, on average, patients 
reported 1.5 days of missed work or school and 1.1 days of lost productivity in the past week, 
translating annually to approximately 75 days and 55 days of lost work and lost productivity, 
respectively. Notwithstanding the likely selection bias in our study, the absenteeism rate is 
markedly higher than the rate observed in the general population, which is reported to be 4.4 days 
per year in the United Kingdom74 and 8.9 days per year in Australia75.  
Limitations of the study are noted. Healthy volunteers were not included as a comparison group, 
because the primary aim was to assess melatonin rhythm phase and compare clinical characteristics 
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of DSPD patients with and without circadian misalignment. Although we used validated 
questionnaires for assessing depressive symptoms and daytime function, we did not include 
diagnostic interviews or objective functional assessments. 
The current findings have implications for both diagnosis and treatment of DSPD. Current 
diagnostic criteria rely almost exclusively on self-reported symptoms, which do not reliably 
distinguish patients with and without an underlying circadian basis for their disorder. We show 
that assessment of circadian phase would greatly improve the diagnosis of DSPD. Better clinical 
assessments will also allow better selection and timing of treatment, potentially leading to 
improved outcomes. Our finding that DSPD illness severity and depression symptoms are elevated 
in DSPD patients with circadian misalignment highlights the importance of circadian phase 
assessment in the diagnosis and optimal management of DSPD, and the potential contribution of 
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Participant Screening  
Participants were included if they met the following criteria: aged 16 to 65 years (equal gender); a body 
mass index > 18 and < 35kg/m2; high risk of DSPD according to established criteria1,72; ≥ 5 consecutive 
days each week in which the individual participates in day work or school; self-reported willingness to go 
to bed at the desired bedtime on the night before work/school days at least 5 nights per week (for the 
purposes of an intervention trial that followed the present study). Participants were excluded if any of the 
following were reported: comorbid sleep disorder (except insomnia); drugs of abuse or concurrent 
medication (including over-the-counter medicines or herbal substances) likely to affect sleep (other than 
antidepressants) without approved discontinuation before study; history of psychiatric disorder in the past 
12 months, other than depression; caffeine consumption > 300 mg per day; alcohol consumption > 14 
standard drinks per week; history of substance abuse in past 12 months; investigational drug use in past 60 
days; pregnancy or lactation; night shift work in past 6 months; transmeridian travel in past 2 months; 
allergies to any medicines, foods, preservatives or dyes; liver, kidney or autoimmune disease. As 
approximately 75% of DSPD patients have a past or current history of depression72, depression was not 
exclusionary. Individuals who had a current diagnosis of depression were required to have shown adequate 
response (determined by prescribing clinician) to antidepressant treatment with at least minimum effective 
dose according to the medication label for 6 weeks prior to enrolment. Additionally, we did not specifically 
exclude participants with sleep initiation insomnia as this type of insomnia is not easily differentiated from 
the symptoms of DSPD. 
Self-report Sleep/Daytime Function Evaluation Measures 
Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ)34 consists of 19 items relating to an 
individual’s preferences for mental and physical activity. The items are either Likert-type, with four or five 
options from which to choose, or time scale responses. A final composite score is calculated when scores 
for individual questions are combined. A higher composite score indicates greater morning preference, 
whilst lower scores indicate greater evening preference. Mid-range scores indicate neither morning or 
evening preference. 
The Epworth Sleepiness Scale (ESS)36 is a self-report assessment of daytime sleepiness, comprised of a list 
of 8 situations in which patients are asked to rate the likelihood of falling asleep on a scale of 0-3, with a 
score of 0 being “no chance” and a score of 3 being “high chance of dozing”. 
 
Sheehan Disability Scale (SDS)37 is a self-report measure assessing functional impairment across three 
domains: work/school, social and family life. Each domain contains a 10-point visual analog scale, 
simultaneously anchored verbally, numerically and spatiovisually. Disability in each domain is rated by the 
participant.  
 
Beck Depression Inventory, Second Edition (BDI-II)38 is a self-report measure assessing the severity of 
depressive symptoms currently being experienced. It contains 21 items describing symptoms of depression 
that participants rate on a scale of 0-3. A total score is obtained by summing scores for each item. Total 




Clinical Global Impressions-Severity Scale (CGI)35 consists of one, observer-rated item, scored on a 7-










Figure 2: Dim light melatonin onset (DLMO) times relative to desired bedtime delayed sleep 
phase disorder and depressive symptom phenotypes. 
  
Mean (± standard error) dim light melatonin onset (DLMO) times relative to desired bedtime for DSPD 
non-circadian (open squares) vs. circadian (solid squares) phenotypes (panel A), and those with minimal 
depressive symptoms (open circles) vs mild-severe symptoms (solid circles) (Panel B). Negative values 
indicate that DLMO time occurs before desired bedtime, and positive values indicate that DLMO occurs 




Figure 3: Prevalence of depressive symptoms in circadian and non-circadian delayed sleep phase 
disorder 
 
Proportion of participants with minimal depression (white), mild depression (grey) and moderate-severe 
depression (black) in circadian and non-circadian DSPD phenotype groups (panel A); Mean (± standard 
error) depressive symptoms (BDI-II score) for circadian and non-circadian DSPD phenotype groups 
(panel B). *p<0.01.  
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Table 1: Participant characteristics 
 
  Circadian Non-circadian p 
N 103 79 
 
Sex n (%) 
49 (47.6) M, 54 
(52.4) F 
40 (50.6) M, 39 
(49.4) F 0.682 
Age (y) 28.7 ± 9.8 31.2 ± 11.5 0.113 
BMI (kg/m
2
) 24.9 ± 4.3 24.4 ± 3.6 0.402 
Employment n (%)   0.309 
Employed, regular hours† 55 (53.4) 50 (63.3)  
Employed, variable shifts†† 2 (1.9) 0 (0)  
Student, full time 45 (43.7) 29 (36.7)  
Student, part time††† 1 (1.0) 0 (0)  
Depression History    
Previous History of Diagnosis n (%)   0.659 
No previous diagnosis 91 (88.3) 68 (86.1)  
Previous diagnosis 12 (11.7) 11 (13.9)  
Current Diagnosis of Depression n (%)   0.759 
No current diagnosis 96 (93.2) 75 (94.9)  
Current diagnosis 7 (6.8) 4 (5.1)  
 
† Regular hours defined as all work hours falling between 6 am and 11 pm (includes paid, unpaid, volunteer 
work, homemaker, or training) 
††Variable shifts defined as work hours including at least 4 hours between 11 pm and 6 am (includes paid, 
unpaid, volunteer work, homemaker, or training) 





Table 2: Self-reported habitual bedtimes and wake times, desired bedtime, daytime function, 





Circadian Non-circadian p 
DLMO Time (h), M ± SD 22:56 ± 1:22 21:16 ± 1:05 <0.001 
DLMO-Habitual Bedtime Phase Angle*    
Work/school nights (h), M ± SD -1.59 ± 1.15 -3.02 ± 1.02 <0.001 
Non-work/school nights (h), M ± SD -2.23 ± 1.40 -3.51 ± 1.36 <0.001 
Desired Bedtime (Work/school nights) (h), M ± SD 22:35 ± 0:56 22:49 ± 0:49 0.093 
Habitual Bedtime    
Work/school nights (h), M ± SD 23:52 ± 1:14 23:52 ± 1:16 0.972 
Non-work/school nights (h), M ± SD 1:08 ± 1:27 0:47 ± 1.23 0.103 
Habitual Wake time    
Work/school nights (h), M ± SD  7:57 ± 1:23 7:54 ± 1:18 0.800 
Non-work/school nights (h), M ± SD  10:52 ± 1:41 10:04 ± 1:42 0.002 
Mood    
Beck Depression Inventory-II, M ± SD 10.55 ± 10.20 7.24 ± 6.02 0.008 
Subjective Daytime Assessment    
Epworth Sleepiness Scale n (%)   0.531 
   ≤10 88 (85.4) 70 (88.6)  
   >10 15 (14.6) 9 (11.4)  
Sheehan Disability Scale M ± SD 15.1 ± 5.4 14.5 ± 5.8 0.482 
Clinical Assessment    
Clinical Global Impressions Scale n (%)   0.015 
   Mildly ill 40 (38.8) 44 (57.1)  
  Moderately-severely ill 63 (61.2) 33 (42.9)  
Diurnal Preference    
Morningness-Eveningness Questionnaire n (%)   0.071 
   Definitely evening  93 (90.3) 64 (81.0)  
   Moderately evening 10 (9.7) 15 (19.0)  
 
Footnote: 
*Phase angle is the difference between DLMO and habitual bedtime (calculated separately for 
work/school nights and non-work/school nights). A negative value indicates that DLMO occurred before 
habitual bedtime. 
 
 
